{"entity":{"type":"insider","cik":"0001759703","url":"/insider/0001759703","json_url":"/insider/0001759703.json","name":"Wiley Matthew T.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2019-03-06","last":"2026-06-26","span_basis":"filed_date"},"name_variants":[{"name":"Wiley Matthew T.","source":"filing","n_filings":6,"first_seen":"2019-03-06","last_seen":"2026-06-26"}],"transactions":[{"id":6018044,"accession":"0001193125-26-285558","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-285558","line_url":"/filing/0001193125-26-285558#line-1","is_derivative":false,"issuer_cik":"0001759703","issuer_name":"Definium Therapeutics, Inc.","issuer_ticker":"DFTX","issuer_name_source":null,"issuer_url":"/issuer/0001759703","owner_cik":"0001759703","owner_name":"Wiley Matthew T.","owner_display_name":"Wiley Matthew T.","owner_url":"/insider/0001759703","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2867.0,"shares_display":"2,867","price_per_share":45.03,"price_display":"45.03","price_state":"stated","total_value":129101.01,"total_display":"129,101.01","total_whole":"129,101","shares_owned_after":174633.0,"shares_owned_after_display":"174,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-25","filed_date":"2026-06-26","scope":"insider"},{"id":2623575,"accession":"0001104659-24-106064","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-106064","line_url":"/filing/0001104659-24-106064#line-2","is_derivative":false,"issuer_cik":"0001720893","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001720893","owner_cik":"0001759703","owner_name":"Wiley Matthew T.","owner_display_name":"Wiley Matthew T.","owner_url":"/insider/0001759703","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6272.0,"shares_display":"6,272","price_per_share":0.55,"price_display":"0.55","price_state":"stated","total_value":3449.6,"total_display":"3,449.60","total_whole":"3,450","shares_owned_after":19011.0,"shares_owned_after_display":"19,011","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-03","filed_date":"2024-10-03","scope":"insider"},{"id":2372562,"accession":"0001104659-24-100746","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-100746","line_url":"/filing/0001104659-24-100746#line-2","is_derivative":false,"issuer_cik":"0001720893","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001720893","owner_cik":"0001759703","owner_name":"Wiley Matthew T.","owner_display_name":"Wiley Matthew T.","owner_url":"/insider/0001759703","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":215.0,"shares_display":"215","price_per_share":0.6908,"price_display":"0.69","price_state":"stated","total_value":148.522,"total_display":"148.52","total_whole":"149","shares_owned_after":4033.0,"shares_owned_after_display":"4,033","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider"},{"id":3268582,"accession":"0001104659-24-073003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-073003","line_url":"/filing/0001104659-24-073003#line-2","is_derivative":false,"issuer_cik":"0001720893","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001720893","owner_cik":"0001759703","owner_name":"Wiley Matthew T.","owner_display_name":"Wiley Matthew T.","owner_url":"/insider/0001759703","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":244.0,"shares_display":"244","price_per_share":1.2627,"price_display":"1.26","price_state":"stated","total_value":308.0988,"total_display":"308.10","total_whole":"308","shares_owned_after":3498.0,"shares_owned_after_display":"3,498","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-17","filed_date":"2024-06-18","scope":"insider"},{"id":2284388,"accession":"0001104659-24-044859","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-24-044859","line_url":"/filing/0001104659-24-044859#line-2","is_derivative":false,"issuer_cik":"0001720893","issuer_name":"BioXcel Therapeutics, Inc.","issuer_ticker":"BTAI","issuer_name_source":null,"issuer_url":"/issuer/0001720893","owner_cik":"0001759703","owner_name":"Wiley Matthew T.","owner_display_name":"Wiley Matthew T.","owner_url":"/insider/0001759703","role":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF COMMERCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF COMMERCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1008.0,"shares_display":"1,008","price_per_share":2.6351,"price_display":"2.64","price_state":"stated","total_value":2656.1808,"total_display":"2,656.18","total_whole":"2,656","shares_owned_after":2992.0,"shares_owned_after_display":"2,992","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-04","filed_date":"2024-04-08","scope":"insider"},{"id":8064730,"accession":"0001209191-19-017304","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-017304","line_url":"/filing/0001209191-19-017304#line-1","is_derivative":false,"issuer_cik":"0001606645","issuer_name":"Foamix Pharmaceuticals Ltd.","issuer_ticker":"FOMX","issuer_name_source":null,"issuer_url":"/issuer/0001606645","owner_cik":"0001759703","owner_name":"Wiley Matthew T.","owner_display_name":"Wiley Matthew T.","owner_url":"/insider/0001759703","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13440.0,"shares_display":"13,440","price_per_share":3.76,"price_display":"3.76","price_state":"stated","total_value":50534.4,"total_display":"50,534.40","total_whole":"50,534","shares_owned_after":63440.0,"shares_owned_after_display":"63,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-05","filed_date":"2019-03-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":5,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001813814","name":"Definium Therapeutics, Inc.","url":"/issuer/0001813814","role":"Officer (Chief Commercial Officer)","n_filings":1,"first_seen":"2026-06-26","last_seen":"2026-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001720893","name":"BioXcel Therapeutics, Inc.","url":"/issuer/0001720893","role":"Officer (Chief Commercial Officer)","n_filings":4,"first_seen":"2024-04-08","last_seen":"2024-10-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001606645","name":"Foamix Pharmaceuticals Ltd.","url":"/issuer/0001606645","role":"Officer (Chief Commercial Officer)","n_filings":1,"first_seen":"2019-03-06","last_seen":"2019-03-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001759703","retrieved_at":"2026-08-26T05:40:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}